![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:735147 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ETFBKMT mRNA | CTD | PMID:21215274, PMID:33387578 | 3,3',4,4',5-pentachlorobiphenyl | decreases expression | ISO | RGD:735147 | 6480464 | 3 more ... | CTD | PMID:23196670 | 4,4'-sulfonyldiphenol | decreases methylation | EXP | | 6480464 | bis(4-hydroxyphenyl)sulfone results in decreased methylation of ETFBKMT gene | CTD | PMID:31601247 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1552244 | 6480464 | Fenretinide results in increased expression of ETFBKMT mRNA | CTD | PMID:28973697 | 6-propyl-2-thiouracil | decreases expression | ISO | RGD:735147 | 6480464 | Propylthiouracil results in decreased expression of ETFBKMT mRNA | CTD | PMID:25825206 | aflatoxin B1 | increases methylation | EXP | | 6480464 | Aflatoxin B1 results in increased methylation of ETFBKMT intron | CTD | PMID:30157460 | amphetamine | increases expression | ISO | RGD:735147 | 6480464 | Amphetamine results in increased expression of ETFBKMT mRNA | CTD | PMID:30779732 | Aroclor 1254 | decreases expression | ISO | RGD:1552244 | 6480464 | Chlorodiphenyl (54% Chlorine) results in decreased expression of ETFBKMT mRNA | CTD | PMID:25270620 | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of ETFBKMT promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of ETFBKMT mRNA | CTD | PMID:32234424 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | RGD:1552244 | 6480464 | Diethylhexyl Phthalate results in decreased expression of ETFBKMT mRNA | CTD | PMID:28085963 | bisphenol A | increases expression | ISO | RGD:1552244 | 6480464 | bisphenol A results in increased expression of ETFBKMT mRNA | CTD | PMID:25594700, PMID:33221593 | bisphenol A | decreases expression | ISO | RGD:735147 | 6480464 | bisphenol A results in decreased expression of ETFBKMT mRNA | CTD | PMID:30816183, PMID:32528016 | bisphenol A | multiple interactions | ISO | RGD:735147 | 6480464 | [bisphenol A co-treated with tributyltin] results in increased expression of ETFBKMT mRNA | CTD | PMID:31129395 | bisphenol A | increases expression | ISO | RGD:735147 | 6480464 | bisphenol A results in increased expression of ETFBKMT mRNA | CTD | PMID:25181051 | butanal | decreases expression | EXP | | 6480464 | butyraldehyde results in decreased expression of ETFBKMT mRNA | CTD | PMID:26079696 | carbon nanotube | decreases expression | ISO | RGD:1552244 | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | carbon nanotube | increases expression | ISO | RGD:1552244 | 6480464 | Nanotubes more ... | CTD | PMID:25620056 | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of ETFBKMT mRNA | CTD | PMID:27392435 | crocidolite asbestos | decreases expression | ISO | RGD:1552244 | 6480464 | Asbestos, Crocidolite results in decreased expression of ETFBKMT mRNA | CTD | PMID:29279043 | Cuprizon | affects expression | ISO | RGD:735147 | 6480464 | Cuprizone affects the expression of ETFBKMT mRNA | CTD | PMID:26577399 | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of ETFBKMT mRNA | CTD | PMID:27989131 | dexamethasone | increases expression | ISO | RGD:1552244 | 6480464 | Dexamethasone results in increased expression of ETFBKMT mRNA | CTD | PMID:22733784 | dioxygen | multiple interactions | ISO | RGD:1552244 | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of ETFBKMT mRNA | CTD | PMID:30529165 | diuron | increases expression | ISO | RGD:735147 | 6480464 | Diuron results in increased expression of ETFBKMT mRNA | CTD | PMID:21551480 | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETFBKMT mRNA | CTD | PMID:27188386 | furan | increases expression | ISO | RGD:735147 | 6480464 | furan results in increased expression of ETFBKMT mRNA | CTD | PMID:27387713 | gentamycin | decreases expression | ISO | RGD:735147 | 6480464 | Gentamicins results in decreased expression of ETFBKMT mRNA | CTD | PMID:33387578 | glycidol | decreases expression | ISO | RGD:735147 | 6480464 | glycidol results in decreased expression of ETFBKMT mRNA | CTD | PMID:24395379 | lead diacetate | increases expression | ISO | RGD:735147 | 6480464 | lead acetate results in increased expression of ETFBKMT mRNA | CTD | PMID:22641619 | lipopolysaccharide | increases expression | ISO | RGD:1552244 | 6480464 | Lipopolysaccharides results in increased expression of ETFBKMT mRNA | CTD | PMID:27339419 | N-nitrosodiethylamine | decreases expression | ISO | RGD:1552244 | 6480464 | Diethylnitrosamine results in decreased expression of ETFBKMT mRNA | CTD | PMID:24535843 | nickel atom | decreases expression | EXP | | 6480464 | Nickel results in decreased expression of ETFBKMT mRNA | CTD | PMID:25583101 | oxaliplatin | multiple interactions | ISO | RGD:735147 | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of ETFBKMT mRNA | CTD | PMID:25729387 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of ETFBKMT mRNA | CTD | PMID:29067470 | paracetamol | decreases expression | ISO | RGD:735147 | 6480464 | Acetaminophen results in decreased expression of ETFBKMT mRNA | CTD | PMID:33387578 | perfluorononanoic acid | increases expression | EXP | | 6480464 | perfluoro-n-nonanoic acid results in increased expression of ETFBKMT mRNA | CTD | PMID:25812627 | perfluorooctane-1-sulfonic acid | increases expression | EXP | | 6480464 | perfluorooctane sulfonic acid results in increased expression of ETFBKMT mRNA | CTD | PMID:25812627 | perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of ETFBKMT mRNA | CTD | PMID:25812627 | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETFBKMT mRNA | CTD | PMID:27188386 | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETFBKMT mRNA | CTD | PMID:27188386 | sodium arsenite | affects methylation | EXP | | 6480464 | sodium arsenite affects the methylation of ETFBKMT gene | CTD | PMID:28589171 | testosterone | multiple interactions | ISO | RGD:1552244 | 6480464 | 1 more ... | CTD | PMID:33848595 | testosterone | increases expression | ISO | RGD:1552244 | 6480464 | Testosterone deficiency results in increased expression of ETFBKMT mRNA | CTD | PMID:33848595 | tetrachloromethane | multiple interactions | ISO | RGD:1552244 | 6480464 | [PANX1 protein co-treated with Carbon Tetrachloride] affects the expression of ETFBKMT mRNA | CTD | PMID:29987408 | tetrachloromethane | decreases expression | ISO | RGD:1552244 | 6480464 | Carbon Tetrachloride results in decreased expression of ETFBKMT mRNA | CTD | PMID:31919559 | tetraphene | increases expression | ISO | RGD:1552244 | 6480464 | benz(a)anthracene results in increased expression of ETFBKMT mRNA | CTD | PMID:26377693 | thioacetamide | decreases expression | ISO | RGD:735147 | 6480464 | Thioacetamide results in decreased expression of ETFBKMT mRNA | CTD | PMID:34492290 | topotecan | multiple interactions | ISO | RGD:735147 | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of ETFBKMT mRNA | CTD | PMID:25729387 | topotecan | decreases expression | ISO | RGD:735147 | 6480464 | Topotecan results in decreased expression of ETFBKMT mRNA | CTD | PMID:25729387 | tributylstannane | multiple interactions | ISO | RGD:735147 | 6480464 | [bisphenol A co-treated with tributyltin] results in increased expression of ETFBKMT mRNA | CTD | PMID:31129395 | trichloroethene | decreases expression | ISO | RGD:1552244 | 6480464 | Trichloroethylene results in decreased expression of ETFBKMT mRNA | CTD | PMID:25549359 | trichloroethene | decreases expression | ISO | RGD:735147 | 6480464 | Trichloroethylene results in decreased expression of ETFBKMT mRNA | CTD | PMID:33387578 | triptonide | affects expression | ISO | RGD:1552244 | 6480464 | triptonide affects the expression of ETFBKMT mRNA | CTD | PMID:33045310 | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of ETFBKMT mRNA | CTD | PMID:23179753, PMID:28001369 | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of ETFBKMT mRNA | CTD | PMID:25979313 | |